Business Wire

Financial year 2018: Boehringer Ingelheim grows and invests

Del

The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2 billion euros (+2.8%), R&D expenses increased to 18.1 per cent of annual net sales.

In the process, the company has focused on specific therapeutic areas. “We want to make a significant contribution towards a superior treatment of cancer,” says Hubertus von Baumbach, Chairman of the Board of Managing Directors. “In addition, we are conducting research, among others, into fibrotic, metabolic and immunological diseases. Our research pipeline is well-filled.”

At almost 1 billion euros (+9%), investments in tangible assets were higher than ever before. Operating income again amounted to 3.5 billion euros (- 0.4%), while Group profit after tax increased to 2.1 billion euros. “In 2018, the return on net sales increased from 19.3 to 19.8 per cent, while our equity ratio rose from nearly 38 per cent to 40 per cent. Thus we are also a very healthy company from a financial point of view,” remarks Michael Schmelmer, Member of the Board of Managing Directors responsible for Finance.

The average number of employees in all regions increased slightly to a total of 50,370 (+2%).

Human pharmaceuticals – strong portfolio

At 12.6 billion euros, human pharmaceuticals contributed to 72 per cent of total net sales in 2018. Foreseeable declines in net sales, due to expiring patents for innovative medicines, were more than compensated for, this business thereby achieving currency-adjusted growth of 5.1 per cent. Revenues from the global licensing business were lower than in the previous year and have reduced the overall rate of growth in this business area to 3.3 per cent.

As in previous years, the respiratory medicine SPIRIVA® achieved the highest net sales contributions with 2.4 billion euros (-11.4% currency-adjusted), followed by the type-2 diabetes medicine family JARDIANCE®, including SYNJARDY® and GLYXAMBI®, with 1.8 billion euros (+52.5% currency-adjusted), the anticoagulant PRADAXA® with 1.5 billion euros (+7.0% currency-adjusted), the type-2 diabetes medicine TRAJENTA® with 1.4 billion euros (+9.0% currency-adjusted), as well as OFEV® for the treatment of idiopathic pulmonary fibrosis (IPF), with 1.1 billion euros (+28.7% currency-adjusted).

At 2.8 billion euros, research and development investments in human pharmaceuticals corresponded to a 22.1% share of human pharmaceuticals’ net sales. For the total of 90 projects in all phases of the research process, the goal is for 75 per cent of them to be either the first molecules in their active ingredient class or the first in a new therapeutic area. In oncology, the focal points are cancers of the lung, stomach and intestine, while in fibrotic diseases the focus is on systemic scleroderma with interstitial lung disease. In metabolic diseases, non-alcoholic steatohepatitis is the main focus of research. In immunology, research is giving attention to chronic inflammatory diseases of the skin and intestine. Other projects address diseases of the central nervous system, such as Alzheimer’s and schizophrenia, obesity and retinopathy.

Animal health – Technical integration completed

In animal health, our focus is on innovative vaccines, antiparasitic medicines and further therapy solutions for livestock and pets. In 2018, the three antiparasitic medicines NEXGARD®, FRONTLINE® and HEARTGARD®, plus the vaccine INGELVAC CIRCOFLEX®, were the four best-selling products. Net sales of 4 billion euros represented 23 per cent of total net sales.

In the second year of the Merial transaction, this business has thereby achieved significant net sales growth, with a currency-adjusted rate of 5.6 per cent, while simultaneously undertaking integration efforts. “We have focused on providing our customers with continuous supply from day one. As a result, we have achieved good growth and the technical integration is successfully completed,” says Hubertus von Baumbach. The innovation potential in animal health, where it interrelates with human pharmaceutical research, deserves particular attention.

Biopharmaceutical contract manufacturing maintains lead position

The biopharmaceuticals business maintained its lead position in the contract manufacturing segment in the financial year 2018 and provided 4 per cent of overall net sales. The order situation has continued to develop positively and provided for a high level of capacity utilization in biopharmaceutical production.

Outlook for 2019

For the current financial year, Boehringer Ingelheim is expecting slight growth in net sales and further intensive investment activities on a comparable basis. “In Europe alone we are planning investments of more than 3 billion euros within the next five years,” says von Baumbach. “The key precondition for this are competitive overall conditions at our European sites.”

Please click on the link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/annualresultspressconference2019

Contact information

Boehringer Ingelheim
Corporate Communications
Media + PR
Matthias Reinig
55216 Ingelheim/Germany
Phone: 06132 – 77 18 48 55
Fax: 06132 – 77 6601
Email: press@boehringer-ingelheim.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Forter Readies Merchants with Launch of PSD2-Compliant Solution25.4.2019 11:25:00 CESTPressemelding

Forter, the leading e-commerce fraud prevention company, today launches its PSD2-compliant merchant offering, Forter PSD2 Solution for Merchants . The comprehensive, payment processor-agnostic solution enables merchants to dynamically route customers to the path of least friction required, prevent all types of fraud and violations of business policies, and optimise the customer’s payment experience – all while meeting full PSD2 compliance. As of 14 September 2019, the revised Payment Services Directive (PSD2) introduces the requirement for merchants to authenticate online transactions within the European Economic Area using Strong Customer Authentication (SCA). Under SCA, merchants have to introduce additional friction into the purchasing process for customers, which will lead to increased drop-off rates, reduce overall conversion rates, and provide a poor customer experience. These changes could ultimately hurt revenue, so merchants must mitigate these challenges and minimise the impa

The Smarter E Europe – Explore Sector Coupling for Yourself at Europe’s Largest Platform for the Energy Industry25.4.2019 09:53:00 CESTPressemelding

The innovation hub The smarter E Europe, encompassing the exhibitions Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power, was launched in 2018 and has seen impressive growth ever since. It will be held for the second time from May 15–17, 2019 at Messe München and will now cover 10 exhibition halls, making it Europe’s largest energy industry event. This growth is due in large part to the upward trend in renewable energies. Since 2010, the proportion of energy generated worldwide from renewable sources has risen from 20 to 25 percent. By 2030, we’re looking at a jump to around 60 percent. In Germany, an average of 45 percent of all electricity generated already came from renewables in the first quarter of 2019. This dynamism is stimulating innovation and shaping the modern energy industry. The buzzword of the hour is sector coupling – a unification of the previously independent electricity, heating and transportation sectors. For instance, a photovoltaic (PV) installation in

The “One and Done” Era for Orphan Drugs: Evaluate Predicts 12% Growth, Driven by New Technologies, but Benefits Go to Big Pharma25.4.2019 07:00:00 CESTPressemelding

Scientific advancements will help propel the orphan drug market to a 12% CAGR to 2024, double the 6% rate expected for non-orphan products. In addition to recent breakthrough cell and gene therapy products like Yescarta and Luxturna, a number of “one and done” treatments for orphan diseases are approaching the market, including Novartis’s Zolgensma and bluebird bio’s Lentiglobin. The explosion of new technologies brings their high price points into greater focus — for example, the $425,000 per eye list price for Spark’s Luxturna is the value-based price agreed on with Spark and payers. In 2018, the mean cost for an orphan drug was 4.5 times that of a non-orphan product. Despite the clear advancements in treatment, however, those calling for reform of the Orphan Drug Act may gain further ammunition. Big pharma continues to entrench their position in the orphan market, as evidenced by Bristol-Myers Squibb’s bid for Celgene, Roche’s pending acquisition of Spark, and Novartis’s $8.7bn paym

NTT Group Increases Capital in NTT Global Data Centers Corp. to Further Strengthen Data Center Business25.4.2019 06:00:00 CESTPressemelding

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), NTT Urban Development Corporation, Nippon Telegraph and Telephone Corporation (NTT Corporation), NTT Finance Corporation announced today that it has increased its capital in NTT Global Data Centers Corporation (NTT GDC), a subsidiary company handling centralized global construction, management and equipment wholesales for NTT group data centers. NTT GDC is capitalized at 1.25 billion JPY, of which 60% will be had share by NTT Com. And three other NTT Group companies newly acquired shares in NTT GDC, namely, NTT Urban Development Corporation (20%), NTT Corporation (10%) and NTT Finance Corporation (10%), all as of today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006195/en/ NTT GDC oversees investment and asset-ownership functions for data center construction. Established last year

China Yiwu Imported Commodities Fair 2019 to Open in May25.4.2019 05:49:00 CESTPressemelding

China Yiwu Imported Commodities Fair 2019, the professional platform for international small commodities to enter China, will open on May 23-26, 2019 at the Yiwu International Expo Center in China’s small commodities paradise Yiwu City. The Fair of this year will cover an exhibition area of over 50,000 square meters, providing 2,000 international standard booths in 4 exhibition zones, namely Asia Pavilion I, Asia Pavilion II, European Pavilion and America-Australia-Africa & Cross-border Trade Pavilion. The imported commodities to be displayed will include household items, maternal and child supplies, beauty and personal care, crafts, home appliances, food and beverage, health and nutrition, fashion accessories, creative toys, stationery, sports goods, clothing and accessories. The Fair is expected to attract over 1,500 business companies and organizations from over 100 countries and regions across the world. The number of visitors and buyers will exceed 120,000. The Import Commodities

Biomedical Software Startup BostonGene Secures $50M in Series A Financing from NEC25.4.2019 01:00:00 CESTPressemelding

NEC Corporation (NEC; TSE: 6701) and BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, today announced a US$50M series A strategic investment in BostonGene by NEC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006170/en/ BostonGene, a pioneer in the use of biomedical software for advanced patient analysis, has discovered, developed, and patented a holistic approach to cancer treatment by defining the optimal therapy combination for individual patients, with a particular focus on immuno- and targeted therapies. BostonGene’s solution includes: Genome and transcriptome sequencing methods to create a patient’s molecular profile. Algorithms that estimate the immune fitness and cancer characteristics of a patient. A continuously updated expert-curated and Artificial Intelligence (AI)-driven database of cancer research and clinical information. Cloud-native software that delivers a patien